XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain, Massachusetts, Boston Beloud

@wfmz.com · 6 hours

XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain

XtalPi Submits U.S. FDA IND Application for KQTD-126, a Potential First-in-Class, Gut-Restricted Pan-TRK Inhibitor for Chronic Intestinal Pain

XtalPi has submitted an Investigational New Drug (IND) application to the U.S. FDA for KQTD-126, a potential first-in-class, gut-restricted pan-TRK inhibitor. Designed to treat chronic intes...

Read more Wfmz.com